Lifesci Capital Downgrades Context Therapeutics (NASDAQ:CNTX) to Hold

Context Therapeutics (NASDAQ:CNTX) was downgraded by analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Other analysts also recently issued reports about the company. Wall Street Zen downgraded Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Weiss Ratings cut shares of Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Citigroup reissued an “outperform” rating on shares of Context Therapeutics in a research report on Thursday. Finally, Maxim Group reduced their price target on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $6.17.

Context Therapeutics Stock Performance

Context Therapeutics stock opened at $0.48 on Thursday. The company has a market capitalization of $44.47 million, a PE ratio of -1.01 and a beta of 1.74. The company has a 50 day moving average price of $0.86 and a 200-day moving average price of $1.91. Context Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.06). On average, analysts forecast that Context Therapeutics will post -0.39 earnings per share for the current year.

Institutional Investors Weigh In On Context Therapeutics

A number of large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Context Therapeutics in the 2nd quarter worth approximately $3,417,000. Octagon Capital Advisors LP purchased a new position in Context Therapeutics in the 1st quarter worth $13,755,000. Millennium Management LLC purchased a new position in shares of Context Therapeutics in the fourth quarter worth about $3,824,000. Marshall Wace LLP lifted its stake in Context Therapeutics by 7,153.7% during the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after acquiring an additional 2,557,448 shares during the period. Finally, Timothy G. Youngquist 2020 Irrevocable Trust purchased a new stake in Context Therapeutics in the second quarter valued at $110,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.